Characteristics

ALC-15/AMC-15 ≥ 1 (N = 120)

ALC-15/AMC-15 < 1 (N = 136)

P-value

At Diagnosis

 

 

 

Age, years, median (range)

55 (22-76)

55 (17-76)

0.2

Gender

 

 

0.4

Male

71 (59.0%)

87 (64.0%)

 

Female

49 (41.0%)

49 (36.0%)

 

Extra-nodal sites

 

 

0.6

0

81 (67.5%)

90 (66.2%)

 

1

31 (26.0%)

33 (24.3%)

 

2

6 (5.0%)

11 (8.1%)

 

3

2 (1.5%)

1 (0.7%)

 

4

0 (0.0%)

1 (0.7%

 

LDH (U/L), median (range)

211 (110-2400)

284 (111-2250)

0.3

PS

 

 

0.1

0

33 (27.5%)

23 (17.0%)

 

1

85 (70.8%)

107 (78.6%)

 

2

2 (1.7%)

6 (4.4%)

 

Stage

 

 

0.9

I

13 (10.8%)

19 (14.0%)

 

II

21 (17.5%)

22 (16.2%)

 

III

26 (21.7%)

31 (22.8%)

 

IV

60 (50.0%)

64 (47.0%)

 

IPI risk factors

 

 

 

Age, years

 

 

0.1

>60

38 (31.7%)

56 (41.7%)

 

≤ 60

82 (68.3%)

80 (58.8%)

 

Extra-nodal sites

 

 

0.5

> 1

8 (6.7%)

13 (9.6%)

 

≤ 1

112 (93.3%)

123 (90.4%)

 

LDH

 

 

<0.04

abnormal

51 (42.5%)

75 (55.2%)

 

normal

69 (57.5%)

61 (44.8%)

 

PS

 

 

0.3

> 1

2 (1.7%)

6 (4.4%)

 

≤ 1

118(98.3%)

130 (95.6%)

 

Stage

 

 

0.8

I/II

34 (28.0%)

41 (30.0%)

 

III/IV

86 (72%)

95 (70.0%)

 

IPI score

 

 

0.1

0

17 (14.0%)

15 (11.0%)

 

1

44 (37.0%)

35 (26.0%)

 

2

41 (34.0%)

60 (44.0%)

 

3

14 (12.0%)

24 (18.0%)

 

4

4 (3.0%)

2 (1.0%

 

IPI

 

 

<0.03

≥ 2

59 (49.0%)

86 (63.0%)

 

< 2

61 (51.0%)

50 (37.0%)

 

At relapse

 

 

 

IPI risk factors

 

 

 

Age-R

 

 

0.2

> 60

41 (35%)

57 (42%)

 

≤ 60

79 (65%)

79 (58%)

 

Extra nodal sites-R

 

 

< 0.01

> 1

7 965)

22 (16%)

 

≤ 1

113 (94%)

114 (84)

 

LDH-R

 

 

<0.0001

abnormal

40 (33%)

80 (59%)

 

normal

80 (67%)

56 (41%)

 

PS-R

 

 

< 0.02

> 1

8 (7%)

22 (16%)

 

≤ 1

112 (93%)

114 (84%)

 

Stage-R

 

 

<0.03

I/II

60 (50%)

49 (36%)

 

III/IV

60 (50%)

87 (64 %)

 

IPI-R

 

 

<0.0004

>2

16 (13%)

44 (32%)

 

≤ 2

104 (87 %)

92 (68%)

 

Pre-transplant Rituximab

 

 

0.3

No

61 (515)

76 (56%)

 

Yes

59 (49%)

60 (445)

 

Number of prior treatments before transplant

 

 

0.1

2

108 (90%)

112 (81%)

 

3

10 (8%)

23 (17%)

 

4

2 (2%)

1 91%)

 

At transplant

 

 

 

Age, years, median (range)

55.5 (22-77)

59 (17-76)

0.2

Outcome prior to transplant

 

 

<0.02

CR

39 (33.0%)

27 (20.0%)

 

PR

81 (67.0%)

109 (80.0%)

 

Conditioning regimens

 

 

0.7

CTX/TBI

2 (2.0%)

4 (3.0%)

 

BEAC

21 (18.0%)

26 (19.0%)

 

BEAM

97 (80.0%)

106 (78.0%)

 

Infused CD34, median (range)

3.56 (2.0-14.85)

3.14 (2.0-11.06)

0.4

Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse; PS = performance status; PS-R; performance status at relapse; Stage-R = stage at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic Index at relapse; CTX= cyclophosphamide; TBI = Total body irradiation: BEAC = BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM = BCNU, etoposide, Ara-C, and melphalan; CR = complete remission; PR = partial response.
Table 2: Patients’ characteristics based on the ALC-15/AMC-15 ratio = 1 versus < 1.